Aptar Requests U.S. FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShield™.


Devices & Services for Lifecycle Management of Crisis Medications and Beyond

Read description

Accelerate & de-risk programs including COVID-19, create differentiation & improve patient outcomes.

Development of a New Chemical Entity and its commercialization requires up to 15 years work and can represent a $2.6 billion investment. Utilization of alternative dosage forms is a means to leverage that investment through life cycle management (LCM). In today’s fast changing global pandemic, repurposing a medication can save lives. Repurposing presents other benefits to LCM including, but not limited to, IP creation and increased market share, access to faster, less complex regulatory pathways, patient empowerment and less reliance on HCPs. Aptar Pharma Services present our platform that facilitates LCM via formulation development, device selection and regulatory-ready packages.

This presentation illustrates case studies including the repurposing of an existing lifesaving therapy to ease administration in an emergency situation, and where the core aim has been to enable simplified access, with a more intuitive, user-friendly method of delivery. We also illustrate potential application of nasal and inhalation delivery platforms for COVID-19 treatments. Success of a project through human factors and the selection of the right regulatory pathway are highlighted. In addition, we consider how customization and connected add-ons can enable differentiation and improve patient outcomes.

The opportunities associated with nasal drug repurposing are not to be sniffed at.

Presented by

Guillaume Brouet Vice-President - Analytical, Regulatory and Scientific Affairs
Guillaume Brouet is Vice-President, Analytical, Regulatory and Scientific Affairs for Aptar Pharma. He has 25 years of experience in the development and qualification of drug delivery systems as well as analytical and formulation development. He has spoken previously at multiple respiratory and nasal drug delivery conferences. Mr. Brouet graduated from Ecole Supérieure de Chimie Organique et Minérale (ESCOM, Paris, France) and earned an Msc in Physical Chemistry, which he obtained at the University of Houston, TX, US.
Julie D. Suman President, Next Breath, an Aptar Pharma company
Julie D. Suman, R.Ph., Ph.D is the Founder of Next Breath, an Aptar Pharma company, and serves as its President. Dr. Suman holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman is co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. She is also a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings at the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce.
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

May 12, 2020 3PM London / 10AM New York 60 min
Watch now
Presented by
Guillaume Brouet Vice-President - Analytical, Regulatory and Scientific Affairs
Julie D. Suman President, Next Breath, an Aptar Pharma company
Read more
Key Learning Objectives
  • How device partners can add value to LCM
  • How you can leverage device expertise to meet patient needs
  • How you can create differentiation and improve patient outcomes through device development
  • Device selection and support for delivery of COVID-19 therapies to the upper and lower respiratory tract
Do you have questions about this webinar ?
Contact us